// App-Quantinova.ai

7548 : The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study.

Researchers

Presenter

  • Constantine Si Lun Tam

Principal Investigators

  • Andrew Warwick Roberts

  • Mary Ann Anderson

  • Sarah-Jane Dawson

  • Rodney J Hicks

  • Christiane Pott

  • David A. Westerman

  • Glenda Burke

  • Sarah Kamel

  • Martin H. Dreyling

  • Mark A Dawson

  • John Francis Seymour

Medical Centers

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Royal Melbourne Hospital, Parkville, Australia

  • Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • University Hospital Schleswig-Holstein, Lubeck, Germany

  • St Vincent's Hospital, Melbourne, Australia

  • Medizinische Klinik und Poliklinik IV, Klinikum der Universitat Munchen, Munich, Germany

Locations

  • Germany

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Mantle cell lymphoma

Biomarkers

  • 18F-fluorodeoxyglucose

  • Cluster of differentiation 69

  • RNA-binding protein FUS/TLS

Drug/Treatment

  • Venetoclax

  • Ibrutinib

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02471391

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved